Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer (Q46799296)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

1 reference

based on heuristic

inferred from title

6

object named as

Mark Clemons

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

author name string

Stephen Johnston

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Mark Basik

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Roberto Hegg

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Wirote Lausoontornsiri

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Lukasz Grzeda

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Lydia Dreosti

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Helen Mann

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Mary Stuart

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Massimo Cristofanilli

10

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

language of work or name

0 references

publication date

21 September 2016

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

160

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

91-99

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3979-5

21 January 2018

Identifiers

10.1007/S10549-016-3979-5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/27654971

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46799296&oldid=2208124635"